AFLIBERCEPT-AYYH | B761298 | AMGEN INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Aug. 23, 2036 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12338274(formulation) · relevance 93/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Approved Biosimilars
0 AI-discovered patents, sorted by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| WVND | 2025-07-31 | Active | — | |
| C.D. Cal. | 2025-06-17 | Terminated 2025-07-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.